WallStreetZenWallStreetZen

NASDAQ: ACRV
Acrivon Therapeutics Inc Stock Ownership - Who owns Acrivon Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Acrivon Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Peter BlumejensenPresident and CEO2026-02-2114,265$1.53
$21.83kSell
Katharine PetersonChief Accounting Officer2026-02-14116$1.63
$189.08Sell
Mary MillerChief Legal Officer2026-02-14217$1.63
$353.71Sell
Peter BlumejensenPresident and CEO2026-02-141,302$1.63
$2.12kSell
Erick GamelinChief Development Officer2026-02-14471$1.63
$767.73Sell
Eric DevroeChief Operating Officer2026-02-14723$1.63
$1.18kSell
Peter BlumejensenPresident and CEO2026-02-14579$1.63
$943.77Sell
Mary MillerChief Legal Officer2026-01-17659$1.98
$1.30kSell
Adam D. LevyChief Financial Officer2026-01-148,832$1.70
$15.00kBuy
Peter BlumejensenPresident and CEO2026-01-1449,000$1.68
$82.12kBuy

1 of 5

ACRV insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ACRV insiders and whales buy or sell their stock.

ACRV Shareholders

What type of owners hold Acrivon Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP26.43%8,340,508$12.59MInstitution
Chione Ltd12.20%3,848,632$5.81MInsider
Kristina Masson11.70%3,691,232$5.57MInsider
Perceptive Advisors LLC9.84%3,104,139$4.69MInsider
Peter Blumejensen8.52%2,688,329$4.06MInsider
Sands Capital Alternatives LLC6.73%2,122,605$3.21MInstitution
Citadel Advisors LLC5.20%1,641,884$2.48MInstitution
Wellington Biomedical Innovation Master Investors Cayman I LP2.81%888,130$1.34MInsider
Wellington Management Group LLP2.81%888,130$1.34MInstitution
Vanguard Group Inc2.21%698,857$1.06MInstitution

1 of 3

ACRV vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ACRV55.67%44.33%Net SellingNet Buying
NERV40.98%59.02%
DOMH9.83%56.66%Net SellingNet Selling
PMN0.95%99.05%Net BuyingNet Buying
LPCN17.10%82.90%
View Top Biotech Stocks

Acrivon Therapeutics Stock Ownership FAQ

Who owns Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ: ACRV) is owned by 58.98% institutional shareholders, 46.97% Acrivon Therapeutics insiders, and 0.00% retail investors. Chione Ltd is the largest individual Acrivon Therapeutics shareholder, owning 3.85M shares representing 12.20% of the company. Chione Ltd's Acrivon Therapeutics shares are currently valued at $5.89M.

If you're new to stock investing, here's how to buy Acrivon Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.